Fed. Circ. Won't Rehear IP Suit Over Hanmi's Nexium Generic
In a brief order that wasn't accompanied by an opinion, the appeals court shot down the petitions by AstraZeneca, which has argued that a Federal Circuit panel disregarded precedent in upholding a lower court’s claim construction, for a panel rehearing and a rehearing en banc.
Mark Boland of...
To view the full article, register now.